Sandoz Takes Legal Action Against Amgen
Sandoz, a prominent player in the field of generic and biosimilar medicines, has officially filed an antitrust lawsuit in the United States against Amgen, Inc. This lawsuit aims to expedite market access for Sandoz's etanercept biosimilar, Erelzi® (etanercept-szzs), a critical treatment for inflammatory diseases affecting millions of Americans.
The Importance of Erelzi®
Erelzi® stands as a significant alternative to the reference medicine Enbrel®, which has seen considerable market success since its FDA approval in 1998. Despite being granted approval by the FDA in 2016, Sandoz reports that Amgen continues to obstruct the launch of Erelzi®, stifling competition and limiting patient access to affordable treatment options. Approximately 7.5 million Americans live with chronic inflammatory conditions, including rheumatoid arthritis and psoriasis, that could benefit from this biosimilar.
The Allegations Against Amgen
Sandoz accuses Amgen of employing unlawful tactics to maintain its dominance in the market, specifically through the acquisition of certain patent rights to suppress competition from biosimilars like Erelzi®. This alleged behavior not only restricts access for patients but also inflates treatment costs considerably. In 2024, sales of Enbrel® reached a staggering USD 3.3 billion in the United States alone, underscoring the substantial financial stakes involved.
Seeking Justice and Damages
As part of the lawsuit, Sandoz is not only asking for an injunction to lift the obstacles imposed by Amgen but is also pursuing damages, which could potentially be tripled based on applicable laws. This dual approach reflects Sandoz's commitment to patient advocacy, aiming to settle the legal dispute in a way that prioritizes public health and patient access.
The Development of Erelzi®
Erelzi® has undergone rigorous testing within a global development program designed to ensure its comparability to Enbrel® at multiple levels, including analytical, preclinical, and clinical phases. The rigorous Phase III confirmatory safety and efficacy study titled EGALITY has cemented Erelzi®'s position as a reliable biosimilar option for a variety of conditions such as adult rheumatoid arthritis, ankylosing spondylitis, and moderate to severe plaque psoriasis. Each indication reflects Sandoz’s commitment to offering high-quality, affordable treatments to patients in need.
Sandoz's Commitment to Pioneering Access
As a leader in the biosimilars market, Sandoz remains driven by its purpose of pioneering access for patients across the globe. With a workforce of over 20,000 individuals from varied backgrounds, the company is dedicated to providing approximately 900 million treatments annually, fostering substantial healthcare savings worldwide. Sandoz's historical significance in the pharmaceutical sector is illustrated by its introduction of groundbreaking treatments, including the world's first oral penicillin and its first biosimilar product in 2006.
In 2024, Sandoz achieved remarkable net sales of USD 10.4 billion, showcasing continual growth and resilience in a competitive industry. The ongoing lawsuit against Amgen is just one aspect of their broader strategy to improve healthcare access for patients, ensuring that innovations reach those who need them.
Conclusion
Sandoz's legal actions against Amgen exemplify the challenges and complexities of navigating the pharmaceutical landscape, especially regarding biosimilars aimed at enhancing patient access to essential medications. With the court case in progress, Sandoz is determined to fight for both access and fair competition, striving to provide innovative treatments for chronic inflammatory diseases in the United States.
Frequently Asked Questions
What is the main reason for Sandoz's antitrust lawsuit against Amgen?
Sandoz is pursuing legal action against Amgen to challenge its practices that allegedly block access to Erelzi®, a biosimilar for Enbrel®, thereby limiting treatment options for patients.
How many Americans are estimated to benefit from Erelzi®?
Approximately 7.5 million Americans living with chronic inflammatory diseases could benefit from the availability of Sandoz's biosimilar Erelzi®.
What specific damages is Sandoz seeking in this lawsuit?
Sandoz is seeking an injunction against Amgen to allow Erelzi® to enter the market, as well as damages that could potentially be tripled under applicable laws.
When did Sandoz receive FDA approval for Erelzi®?
Sandoz received FDA approval for Erelzi® in 2016, yet its market launch has been hindered by Amgen's actions.
What is the significance of the revenue generated by Enbrel®?
Enbrel® generated USD 3.3 billion in the US in 2024, illustrating the significant financial impact and competition in the market for inflammatory disease treatments.
